<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3155">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04341870</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200375-3</org_study_id>
    <nct_id>NCT04341870</nct_id>
  </id_info>
  <brief_title>Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO</brief_title>
  <acronym>CORIMUNO-VIRO</acronym>
  <official_title>Efficacy of Sarilumab + Azithromycin + Hydroxychloroquine, and Sarilumab Alone, for Adult Patients Hospitalized With Moderate to Severe COVID-19: a Multicenter Open-label 1:1 Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of the study is to determine the therapeutic effect and tolerance of&#xD;
      Sarilumab in combination with Azithromycin and Hydroxychloroquine, compared to Sarilumab&#xD;
      only, patients with moderate, severe pneumonia associated with Coronavirus disease 2019&#xD;
      (COVID-19). Sarilumab is a human IgG1 monoclonal antibody that binds specifically to both&#xD;
      soluble and membrane-bound IL-6Rs (sIL-6Rα and mIL-6Rα) and has been shown to inhibit&#xD;
      IL-6-mediated signaling through these receptors. The study has a cohort multiple Randomized&#xD;
      Controlled Trials (cmRCT) design. Randomization will occur prior to offering investigational&#xD;
      treatments administration to patients enrolled in the CORIMUNO-19 cohort (NCT04324047).&#xD;
      Sarilumab+Azithromycin+Hydroxychloroquine, or Sarilumab only will be administered to&#xD;
      consenting adult patients hospitalized with COVID-19 either diagnosed with moderate or severe&#xD;
      pneumonia requiring no mechanical ventilation. All patients will receive standard of care&#xD;
      along with randomized investigational treatments. Outcomes of included patients will be&#xD;
      compared between groups as well as with outcomes of patients in the CORIMUNO-19 cohort&#xD;
      treated with other immune modulators or standard of care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    DSMB recommendation (futility)&#xD;
  </why_stopped>
  <start_date type="Actual">April 11, 2020</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">May 8, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Bayesian open labelled randomized clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Need for ventilation (including invasive and non invasive ventilation), intensive care or death</measure>
    <time_frame>14 days</time_frame>
    <description>Events considered are: need for ventilation (including invasive and non invasive ventilation), transfer to the Intensive Care Unit, death or new do-not-resuscitate (DNR) decision in the absence ventilation and outside ICU.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early improvement: OMS progression scale &lt;= 5</measure>
    <time_frame>4 days</time_frame>
    <description>WHO progression scale: Uninfected; non viral RNA detected: 0 Asymptomatic; viral RNA detected: 1 Symptomatic; Independent: 2 Symptomatic; Assistance needed: 3 Hospitalized; No oxygen therapy: 4 Hospitalized; oxygen by mask or nasal prongs: 5 Hospitalized; oxygen by NIV or High flow: 6 Intubation and Mechanical ventilation, pO2/FIO2&gt;=150 OR SpO2/FIO2&gt;=200: 7 Mechanical ventilation, (pO2/FIO2&lt;150 OR SpO2/FIO2&lt;200) OR vasopressors (norepinephrine &gt;0.3 microg/kg/min): 8 Mechanical ventilation, pO2/FIO2&lt;150 AND vasopressors (norepinephrine &gt;0.3 microg/kg/min), OR Dialysis OR ECMO: 9 Dead: 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OMS progression scale</measure>
    <time_frame>4, 7 and 14 days</time_frame>
    <description>WHO progression scale: Uninfected; non viral RNA detected: 0 Asymptomatic; viral RNA detected: 1 Symptomatic; Independent: 2 Symptomatic; Assistance needed: 3 Hospitalized; No oxygen therapy: 4 Hospitalized; oxygen by mask or nasal prongs: 5 Hospitalized; oxygen by NIV or High flow: 6 Intubation and Mechanical ventilation, pO2/FIO2&gt;=150 OR SpO2/FIO2&gt;=200: 7 Mechanical ventilation, (pO2/FIO2&lt;150 OR SpO2/FIO2&lt;200) OR vasopressors (norepinephrine &gt;0.3 microg/kg/min): 8 Mechanical ventilation, pO2/FIO2&lt;150 AND vasopressors (norepinephrine &gt;0.3 microg/kg/min), OR Dialysis OR ECMO: 9 Dead: 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>14, 28 and 90 days</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-free days alive</measure>
    <time_frame>14, 28 and 90 days</time_frame>
    <description>Number of ICU-free days alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilation-free days alive</measure>
    <time_frame>14 and 28 days</time_frame>
    <description>Number of ventilation(invasive or non invasive)-free days alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital-free days alive</measure>
    <time_frame>14, 28 and 90 days</time_frame>
    <description>Number of hospital-free days alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen therapy-free days alive</measure>
    <time_frame>14 and 28 days</time_frame>
    <description>Number of oxygen therapy-free days alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to negative viral excretion</measure>
    <time_frame>90 days</time_frame>
    <description>SARS-CoV-2 viral load measurement by rtPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunophenotyping and multiplex cytokines</measure>
    <time_frame>8 days</time_frame>
    <description>Immunophenotyping and multiplex cytokines (blood sample)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>COVID19</condition>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Sarilumab + Azithromycin + Hydroxychloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sarilumab combined with Azithromycin and Hydroxychloroquine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarilumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sarilumab only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sarilumab</intervention_name>
    <description>Sarilumab: 400 mg in a 1 hour - I.V. infusion on D1</description>
    <arm_group_label>Sarilumab</arm_group_label>
    <arm_group_label>Sarilumab + Azithromycin + Hydroxychloroquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Azithromycin: oral administration, 500mg on D1 then 250mg QD on D2 to D5 (total duration 5 days)</description>
    <arm_group_label>Sarilumab + Azithromycin + Hydroxychloroquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Hydroxychloroquine: oral administration, 600mg QD (200mg TID) from D1 to D10 (total duration 10 days)</description>
    <arm_group_label>Sarilumab + Azithromycin + Hydroxychloroquine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients included in the CORIMUNO-19 cohort (NCT04324047)&#xD;
&#xD;
          -  COVID-19 cases not requiring ICU at admission with moderate or severe pneumopathy&#xD;
             according to the WHO Criteria of severity of COVID pneumopathy:&#xD;
&#xD;
               -  Moderate cases: Cases meeting all of the following criteria: [Showing fever and&#xD;
                  respiratory symptoms with radiological findings of pneumonia] AND [Requiring&#xD;
                  between 3L/min and 5L/min of oxygen to maintain SpO2&gt;97%] OR&#xD;
&#xD;
               -  Severe cases: Cases meeting any of the following criteria: [Respiratory distress&#xD;
                  ( ≥ 30 breaths/ min)] OR [Oxygen saturation≤93% at rest in ambient air; or Oxygen&#xD;
                  saturation ≤97 % with O2 &gt; 5L/min] OR [PaO2/FiO2 ≤ 300mmHg]&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with exclusion criteria to the CORIMUNO-19 cohort.&#xD;
&#xD;
          2. Respiratory failure requiring non invasive or mechanical ventilation&#xD;
&#xD;
          3. Patients requiring intensive care&#xD;
&#xD;
          4. Do-not-resuscitate order (DNR order)&#xD;
&#xD;
          5. Known hypersensitivity to sarilumab or to any of their excipients.&#xD;
&#xD;
          6. Known contra-indication to hydroxychloroquine or chloroquine: including&#xD;
             hypersensitivity/allergy, retinopathy, G6PD deficiency and QT prolongation&#xD;
&#xD;
          7. Known contra-indication to azithromycin: including hypersensitivity/allergy and QT&#xD;
             prolongation&#xD;
&#xD;
          8. Pregnancy or breastfeeding&#xD;
&#xD;
          9. Current documented bacterial infection.&#xD;
&#xD;
         10. Patient with any of following laboratory results out of the ranges detailed below at&#xD;
             screening should be discussed depending of the medication:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≤ 1.0 x 109/L&#xD;
&#xD;
               -  Haemoglobin level: no limitation&#xD;
&#xD;
               -  Platelets (PLT) &lt; 50 G /L&#xD;
&#xD;
               -  SGOT or SGPT &gt; 5N&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AP-HP Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Ambroise Paré</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 6, 2020</study_first_submitted>
  <study_first_submitted_qc>April 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2020</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

